13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q3 2025 · Filed November 10, 2025 · Accession 0001193125-25-274459
Total Value
$212.5M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Lenz Therapeutics, Inc. | LENZ | 2,656,888 | $123.8M | 58.25% |
| 2 | Monte Rosa Therapeutics, Inc. | GLUE | 5,652,922 | $41.9M | 19.72% |
| 3 | Jade Biosciences, Inc. | JBIO | 1,525,820 | $13.2M | 6.20% |
| 4 | CRISPR Therapeutics AG | CRSP | 148,831 | $9.6M | 4.54% |
| 5 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $7.9M | 3.71% |
| 6 | Contineum Therapeutics, Inc. | CTNM | 542,628 | $6.4M | 3.00% |
| 7 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $4.7M | 2.19% |
| 8 | Tempest Therapeutics, Inc. | TPST | 269,772 | $2.8M | 1.31% |
| 9 | Adverum Biotechnologies, Inc. | 00773U108 | 506,821 | $2.3M | 1.08% |